<?xml version="1.0" encoding="UTF-8"?>
<p id="para240">Another way to fight the virus, apart from stopping it replicating, is to follow our immune system's lead and look to 
 <ext-link ext-link-type="uri" xlink:href="https://www.newscientist.com/article/2237742-how-soon-will-we-have-a-coronavirus-vaccine-the-race-against-covid-19/" id="interrefs200" xmlns:xlink="http://www.w3.org/1999/xlink">antibodies</ext-link>. Biotech start-up AbCellera, based in Vancouver, began this process by rapidly identifying all the antibodies in a blood sample taken from someone who had recovered from covid-19. The company then tested them for their activity against the new coronavirus. Within a week of receiving the sample, AbCellera had identified 500 promising antibodies among the millions, or even billions, in the sample, says 
 <ext-link ext-link-type="uri" xlink:href="https://www.abcellera.com/team" id="interrefs210" xmlns:xlink="http://www.w3.org/1999/xlink">Ester Falconer</ext-link>, the company's head of research and development. It is now working with Indiana-based drugs firm Eli Lilly to develop an antibody-based therapy for covid-19 and have it ready for testing with a faster-than-ever turnaround. “In four months, we can do something that normally takes five to 10 years,” says Falconer.
</p>
